3-羟基-5-硝基苯甲酸甲酯 | 55076-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-羟基-5-硝基苯甲酸甲酯
• 英文名称: methyl 3-hydroxy-5-nitrobenzoate
• 英文别名: methyl 3-nitro-5-hydroxybenzoate；3-hydroxy-5-nitrobenzoic acid methyl ester；3-Hydroxy-5-nitrobenzoesaeure-methylester
• CAS: 55076-32-9
• 化学式: C₈H₇NO₅
• mdl: MFCD00463877
• 分子量: 197.147
• InChiKey: HTYJYEKZUXJKKW-UHFFFAOYSA-N

物化性质

• 熔点：
  154-156 °C
• 沸点：
  377.2±27.0 °C(Predicted)
• 密度：
  1.432±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2918290000

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-hydroxy-5-nitrobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-hydroxy-5-nitrobenzoate
CAS number: 55076-32-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7NO5
Molecular weight: 197.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-羟基-5-硝基苯甲酸甲酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 caesium carbonate 、 溶剂黄146 、 联硼酸频那醇酯 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.5h， 生成 3-((7-(2,4-dimethylpyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)-5-isopropoxybenzoic acid
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  该发明涉及取代喹啉衍生物。具体而言，该发明涉及符合以下式（I）的化合物：其中R1、R2、R3；R4；和R5在此处被定义。该发明的化合物是乳酸脱氢酶A的抑制剂，可用于治疗癌症和与肿瘤细胞代谢相关的疾病，如乳腺癌、结肠癌、前列腺癌和肺癌等。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗相关疾病的方法。

  公开号：

  WO2013096151A1
• 作为产物：
  描述：

  3-羟基-5-硝基苯甲酸 在 硫酸 、 sodium carbonate 作用下， 以 甲醇 、 水 为溶剂， 生成 3-羟基-5-硝基苯甲酸甲酯
  参考文献：
  名称：

  Trisubstituted carbocyclic cyclophilin binding compounds and their use

  摘要：

  本发明涉及一种新型的非肽类小有机化合物，其具有与环肽亚精蛋白（CyP）型免疫蛋白亲和力，并且涉及包含所述化合物中的一个或多个的药物组合物。该发明还涉及这些化合物和组合物用于结合CyP型蛋白，抑制其肽基脯氨酸异构酶活性，并在各种医学疾病的研究、开发和治疗应用中的用途。

  公开号：

  US20020165275A1

文献信息

• Ruthenium-Catalyzed Hydroarylation and One-Pot Twofold Unsymmetrical C−H Functionalization of Arenes
  作者：Koushik Ghosh、Raja K. Rit、E. Ramesh、Akhila K. Sahoo

  DOI：10.1002/anie.201600649

  日期：2016.6.27

  excellent yields. A one‐pot, unsymmetrical, twofold C−H functionalization involving intramolecular C−C and intermolecular C−C/C−N bond formations is successfully demonstrated by using a single set of catalytic reaction conditions, which is unprecedented thus far. A novel isoquinolone‐bearing dihydrobenzofuran is constructed through an unsymmetrical twofold C−H functionalization.

  甲基苯基硫肟亚胺（MPS）用作链烯基苯甲酸衍生物在钌催化的分子内氢芳基化反应中的导向基团，从而以良好或优异的收率提供二氢苯并呋喃和二氢吲哚。通过使用一组催化反应条件成功地证明了涉及分子内C-C和分子间C-C / C-N键形成的单锅，不对称，双重CH功能化，这是迄今为止前所未有的。通过不对称的双重CH官能团构建了一种新型的带有异喹诺酮的二氢苯并呋喃。
• [EN] NEOSEPTINS: SMALL MOLECULE ADJUVANTS<br/>[FR] NÉOSEPTINES : PETITS ADJUVANTS MOLÉCULAIRES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014131023A1

  公开（公告）日：2014-08-28

  A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

  揭示了一种MD-2:TLR4复合物激动剂化合物，其结构对应于所定义的公式（I）。还公开了其制备和使用方法，以及含有该化合物的药物组合物。
• IMIDAZOPYRIDINE COMPOUNDS
  申请人：Iwata Hidehisa

  公开号：US20100069431A1

  公开（公告）日：2010-03-18

  Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.

  提供了用于与葡萄糖激酶一起使用的化合物、药物组合物、试剂盒和方法，其中包括从以下公式(I)所述的组中选择的化合物，其中变量如本文所定义。
• Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site
  作者：Donald J. Abraham、David M. Gazze、Paul E. Kennedy、Michael Mokotoff

  DOI：10.1021/jm00378a005

  日期：1984.12

  This paper reports the discovery of a new class of potent antigelling agents. The new compounds, disubstituted benzoic acid derivatives, were designed by using molecular modeling experiments. These molecules contain functional groups positioned to interact with several polar amino acid residues near the Val-6 beta mutation site (donor site) in HbS. The compounds also contain a hydrophobic group designed

  本文报道了新型强力抗凝胶剂的发现。通过分子模拟实验设计了新化合物二取代苯甲酸衍生物。这些分子包含定位成与HbS中Val-6 beta突变位点（供体位点）附近的几个极性氨基酸残基相互作用的官能团。这些化合物还包含一个疏水基团，该基团设计成在由几个疏水性氨基酸产生的蛋白质表面上占据一个非极性的ara。报道了使用标准溶解度测定法合成和测试这些新分子。在活性最强的抗胶凝剂之一化合物13和苯扎贝特之间进行结构比较，化合物13对溶液中Hb的氧亲和力影响很小 一种已知的抗血脂药物，该药物具有促进作用，并且对降低Hb氧亲和力具有非常有效的作用（Perutz，MF; Poyart，C. Lancet 1983，2，881-882）。我们还报告了合成和测试的一系列脯氨酸-水杨酸分子设计用于在突变受体区域共价反应。这类分子没有显示出明显的活性。
• [EN] DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DÉRIVÉS D'ALCOOLS 1-PHÉNYL-2-PYRIDINYL ALKYLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：CHIESI FARMA SPA

  公开号：WO2012168226A1

  公开（公告）日：2012-12-13

  The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of formula (I), methods of preparing such compounds, compositions containing them and therapeutic use thereof.

  这项发明涉及磷酸二酯酶4（PDE4）的抑制剂。更具体地，该发明涉及公式（I）的1-苯基-2-吡啶基烷基醇衍生物化合物，制备这类化合物的方法，含有这些化合物的组合物以及它们的治疗用途。